Rensing U F, Bestehorn H P, Roskamm H, Petersen J, Betz P, Spinder M, Benesch L, Schemeitat K, Blümchen G, Claus J, Wieland H, Böcker J F, Neiss A, Stiepel E, Mathes P, Kappenberger L, Braunagel K, Peters K, Meister G, Samek L, Schuon J, Leimenstoll B, Kiefer H
Herz-Zentrum, Bad Krozingen.
Z Kardiol. 1999 Apr;88(4):270-82. doi: 10.1007/s003920050286.
The CIS was undertaken with the aim to evaluate the effects of lipid modifications on angiographic progression and regression of CAD in patients with CAD and hypercholesterolemia. The design included a multicenter randomized, double-blind, parallel, placebo-controlled comparison, with target and safety limits for adjusting the trial medication depending on the LDL cholesterol level (LDL-C) achieved, i.e., up to 40 mg of simvastatin (S) or placebo (P) daily, add-on medication (up to 3 x 4 g Colestyramin), and diet counselling. Male patients, average age 49 (< or = 56) years, were included with angiographic CAD and a screening total cholesterol of 207-350 mg/dl, who were not due to undergo coronary bypass surgery or PTCA, who did not suffer from serious other disease (e.g., diabetes mellitus), and who had not undergone coronary bypass surgery previously.
All baseline variables were comparable in the treatment groups, with 129 patients taking S and 125 taking P. Of these 254 patients 217 had their final study visit and 207 underwent a second angiography after an average treatment time of 2.3 years under an average daily dose of 37 mg S. 205 pairs of films were available for analysis. Vital information was obtained of all patients until closure of the data bank, half a year after the last study angiography. Five deaths occurred within the study period, 12 through March 15, 1995 (S: 1/6, P: 4/6). 37 patients (S: 18, P: 19) discontinued trial drug and protocol. Concomitant CAD medication was comparable in both groups, except lipid-lowering add-on medication which was significantly higher in the P group (38% versus 13%). Significant changes in lipid levels, on treatment, were observed in the S group amounting to a mean difference in LDL-C of -35%, in Apo-Protein B (ApoB) of -30%, in VLDL-C of -37%, and in triglycerides (TG) of -27%, and in HDL-C of +6%, in comparison to the control group; these differences were even greater in 137 fully compliant patients: -41, -36, -39, -31, and +7%, respectively. Progression in the S group was significantly less, as defined by the two primary target criteria: 1) the minimum obstruction diameter (MOD), determined by quantitative coronary angiography (QCA), decreased about five times less in comparison to the control group (S: by -0.017; P: -0.0954 mm), and 2) the standardized visual global change score (GCS) deteriorated almost three times less in the S group (by +0.20) than in the P group (+0.58). Of the secondary target criteria, the mean lumen diameter (QCA) also developed a significant difference (S: -0.20; P: +0.23 mm; p = 0.0006) with a trend toward regression in the S group. The QCA-%-stenosis deteriorated three- to four-times less in the S group as compared to the control group (S: by 0.69%; P: by 2.73%; p = 0.0022), and the number of patients with angiographic progression was nearly halved (S: 30%; P: 56%; p < 0.0000). These differences were determined by intention to treat analysis (ITT), and they were obtained in spite of lipid lowering add-on medication in 38% of the P patients; they turned out to be more pronounced in 137 fully compliant patients, in an analysis "as treated". The mean decrease in LDL-C serum level caused by S was significantly correlated to the decrease in progression, and multivariate regression analysis of both treatment groups identified LDL-C (or ApoB) and TG as independent predictors of progression. Progression appeared to be most pronounced in low and medium sized lesions, and the beneficial effect of lipid intervention dominated in lesions with 12-56% QCA stenosis severity. A small fraction of patients who suffered from exercise-induced angina, with ST-segment-depression at the beginning of the study, experienced a significant improvement under S as compared to P treatment. Although the study was not designed to show differences in clinical events, the combined number of all major cardiovascular events tended to be less frequent in the S than in the C gr
进行CIS的目的是评估脂质修饰对患有冠心病(CAD)和高胆固醇血症患者CAD血管造影进展和消退的影响。该设计包括一项多中心随机、双盲、平行、安慰剂对照比较,根据达到的低密度脂蛋白胆固醇水平(LDL-C)调整试验药物的目标和安全限度,即每日最多40毫克辛伐他汀(S)或安慰剂(P)、附加药物(最多3×4克考来烯胺)以及饮食咨询。纳入的男性患者平均年龄49(≤56)岁,患有血管造影确诊的CAD且筛查总胆固醇为207 - 350毫克/分升,不计划进行冠状动脉搭桥手术或经皮冠状动脉腔内血管成形术(PTCA),没有其他严重疾病(如糖尿病),且此前未接受过冠状动脉搭桥手术。
治疗组间所有基线变量具有可比性,129例患者服用S,125例患者服用P。这254例患者中,217例完成了最终研究访视,207例在平均每日剂量37毫克S的情况下平均治疗2.3年后接受了第二次血管造影。有205对胶片可供分析。在数据库关闭前,即最后一次研究血管造影半年后,获取了所有患者的重要信息。研究期间发生5例死亡,截至1995年3月15日有12例(S组:1/6;P组:4/6)。37例患者(S组:18例;P组:19例)停用试验药物和方案。两组伴随的CAD药物具有可比性,但P组的降脂附加药物显著更高(38%对13%)。与对照组相比,S组治疗时血脂水平有显著变化,LDL-C平均差异为 - 35%,载脂蛋白B(ApoB)为 - 30%,极低密度脂蛋白胆固醇(VLDL-C)为 - 37%,甘油三酯(TG)为 - 27%,高密度脂蛋白胆固醇(HDL-C)为 + 6%;在137例完全依从的患者中这些差异更大,分别为 - 41%、 - 36%、 - 39%、 - 31%和 + 7%。根据两个主要目标标准,S组的进展显著更少:1)通过定量冠状动脉造影(QCA)确定的最小阻塞直径(MOD),与对照组相比减少约五分之一(S组: - 0.017;P组: - 0.0954毫米),2)S组标准化视觉整体变化评分(GCS)恶化程度比P组( + 0.58)少近三倍( + 0.20)。在次要目标标准中,平均管腔直径(QCA)也出现显著差异(S组: - 0.20;P组: + 0.23毫米;p = 0.0006),S组有回归趋势。与对照组相比,S组QCA狭窄百分比恶化程度减少三到四倍(S组:0.69%;P组:2.73%;p = 0.0022),血管造影进展的患者数量几乎减半(S组:30%;P组:56%;p < 0.0000)。这些差异通过意向性分析(ITT)确定,尽管P组38%的患者使用了降脂附加药物,但仍得出这些差异;在“实际治疗”分析中,这些差异在137例完全依从的患者中更为明显。S导致的LDL-C血清水平平均下降与进展的减少显著相关,对两个治疗组的多变量回归分析确定LDL-C(或ApoB)和TG是进展的独立预测因素。进展在中小尺寸病变中似乎最为明显,脂质干预的有益效果在QCA狭窄严重程度为12 - 56%的病变中占主导。一小部分在研究开始时患有运动诱发心绞痛且有ST段压低的患者,与P治疗相比,S治疗下有显著改善。尽管该研究并非旨在显示临床事件的差异,但S组所有主要心血管事件的合并数量往往比对照组少。